AI Summary

Researchers at Tel Aviv University reported that the experimental drug Davunetide markedly slowed progression of progressive supranuclear palsy (PSP) in women, while men showed a different response. The team, led by Prof. Illana Gozes, reanalyzed data from a 52‑week international trial that enrolled over 300 PSP patients using updated FDA‑recommended outcome measures. PSP is a rare, fatal neurodegenerative disease caused by abnormal tau protein accumulation, and no effective drug treatment currently exists. The findings highlight the importance of sex‑specific approaches in treating neurodegenerative disorders.

AI summaries can be wrong sometimes—always verify important details using the source article.